Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPN1TW)

• Drug Name: Dofetilide Drug Info
• Synonyms: Dofetilida; Dofetilidum; Tikosyn; Xelide; UK 68798; Dofetilida [INN-Spanish]; Dofetilidum [INN-Latin];Tikosyn (TN); UK 68,798; UK-68798; Dofetilide [USAN:BAN:INN]; Tikosyn, UK68798, Dofetilide; UK-68,798; Dofetilide (JAN/USAN/INN); Beta-((p-Methanesulfonamidophenethyl)methylamino)methanesulfono-p-phenetidide; N-[4-[2-[2-[4-(methanesulfonamido)phenoxy]ethyl-methylamino]ethyl]phenyl]methanesulfonamide; N-(4-{2-[methyl(2-{4-[(methylsulfonyl)amino]phenoxy}ethyl)amino]ethyl}phenyl)methanesulfonamide; Methanesulfonamide, N-(4-(2-(methyl(2-(4-((methylsulfonyl)amino)phenoxy)ethyl)amino)ethyl)phenyl); 1-(4-methanesulfonamidophenoxy)-2-(N-(4-methanesulfonamidophenethyl)-N-methylamine)ethane; 1-MSPMPE

Indication

Disease Entry	ICD 11	Status	REF
Sinus rhythm disorder	BC9Y	Approved	[1]

• Therapeutic Class: Antiarrhythmic Agents
• Cross-matching ID:
  PubChem CID: 71329
  ChEBI ID: CHEMBL473
  CAS Number: CAS 115256-11-6
  TTD Drug ID: DMPN1TW
  VARIDT Drug ID: DR00724
  INTEDE Drug ID: DR0522
  ACDINA Drug ID: D00208

Molecule-Related Drug Atlas

Drug(s) Targeting Potassium channel unspecific (KC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nateglinide	DMLK2QH	Diabetic complication	5A2Y	Approved	[2]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[2]
Dronedarone	DMA8FS5	Angina pectoris	BA40	Approved	[6]
Amifampridine	DMK08L3	LambertEaton myasthenic syndrome	8C62	Approved	[7]
Minoxidil	DMA2Z4F	Alopecia	ED70	Approved	[2]
Pinacidil	DMRADYL	High blood pressure	BA00	Approved	[2]
Dalfampridine	DMM0PDO	Multiple sclerosis	8A40	Approved	[8]
Ibutilide	DMKXY2R	Atrial fibrillation	BC81.3	Approved	[2]
Diazoxide	DML1538	Congenital hyperinsulinism	5A4Y	Approved	[2]
Azimilide	DMUIBV8	Atrial fibrillation	BC81.3	Phase 3	[9]

Drug(s) Transported By Organic cation transporter 2 (SLC22A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[10]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[11]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[12]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[13]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[14]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[15]
Ergotidine	DM78IME	Osteoarthritis	FA00-FA05	Approved	[16]
Metformin	DM89QE1	Colorectal carcinoma		Approved	[17]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[15]
Ranitidine	DM0GUSX	Gastric ulcer	DA60	Approved	[18]

Drug(s) Transported By Multidrug and toxin extrusion protein 1 (SLC47A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aciclovir	DMYLOVR	Genital herpes	1A94	Approved	[19]
Metformin	DM89QE1	Colorectal carcinoma		Approved	[20]
Ganciclovir	DM1MBYQ	Cytomegalovirus infection	1D82	Approved	[19]
Cimetidine	DMH61ZB	Acid-reflux disorder	DA22	Approved	[19]
Chloroquine	DMSI5CB	Malaria	1F40-1F45	Approved	[21]
Procainamide	DMNMXR8	Ventricular arrhythmias	BC71	Approved	[19]
Topotecan	DMP6G8T	Central nervous system neoplasm		Approved	[19]
Cephalexin	DMD5JU8	Acute otitis media	AB00	Approved	[22]
LY2835219	DM93VBZ	Breast cancer	2C60-2C65	Approved	[23]
Pyrimethamine	DM5X7VY	Malaria	1F40-1F45	Approved	[24]

Drug(s) Transported By Multidrug and toxin extrusion protein 2 (SLC47A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aciclovir	DMYLOVR	Genital herpes	1A94	Approved	[19]
Metformin	DM89QE1	Colorectal carcinoma		Approved	[19]
Ganciclovir	DM1MBYQ	Cytomegalovirus infection	1D82	Approved	[19]
Cimetidine	DMH61ZB	Acid-reflux disorder	DA22	Approved	[19]
Procainamide	DMNMXR8	Ventricular arrhythmias	BC71	Approved	[19]
Topotecan	DMP6G8T	Central nervous system neoplasm		Approved	[19]
LY2835219	DM93VBZ	Breast cancer	2C60-2C65	Approved	[23]
Estrone sulfate	DMVBIZL	Atrophic vaginitis	GA30.2	Approved	[19]
N-methylpyridinium	DMVUKEW	N. A.	N. A.	Preclinical	[19]
[14C]TEA	DM6SFYH	Discovery agent	N.A.	Investigative	[19]

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[25]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[26]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[27]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[28]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[29]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[30]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[31]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[32]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[26]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[33]

Drug(s) Affected By Sodium channel protein type 5 subunit alpha (SCN5A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Disopyramide	DM5SYZP	Long QT syndrome	BC65.0	Approved	[5]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[34]
Flecainide	DMSQDLE	Tachyarrhythmias	BC71	Approved	[35]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[36]
Meloxicam	DM2AR7L	Arthritis	FA20	Approved	[37]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[38]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[39]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[40]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[41]
Retigabine	DMGNYIH	Behcet disease	4A62	Approved	[42]

Drug(s) Affected By Potassium voltage-gated channel subfamily E member 1 (KCNE1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[43]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[44]
Pentobarbital	DMFNH7L	Brain ischaemia	8B1Z	Approved	[45]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[5]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[5]
Diltiazem	DMAI7ZV	Angina pectoris	BA40	Approved	[5]
Sotalol	DML60TN	Sinus rhythm disorder	BC9Y	Approved	[5]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[5]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[5]
Atenolol	DMNKG1Z	Angina pectoris	BA40	Approved	[5]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Potassium channel unspecific (KC)	TT1VOHK	NOUNIPROTAC	Modulator	[2]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Multidrug and toxin extrusion protein 2 (SLC47A2)	DT3TX4H	S47A2_HUMAN	Substrate	[3]
Multidrug and toxin extrusion protein 1 (SLC47A1)	DTZGT0P	S47A1_HUMAN	Substrate	[3]
Organic cation transporter 2 (SLC22A2)	DT9IDPW	S22A2_HUMAN	Substrate	[3]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[4]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Potassium voltage-gated channel subfamily E member 1 (KCNE1)	OTZNQUW9	KCNE1_HUMAN	Drug Response	[5]
Sodium channel protein type 5 subunit alpha (SCN5A)	OTGYZWR6	SCN5A_HUMAN	Drug Response	[5]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2604).
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [3] FDA Drug Development and Drug Interactions
• [4] Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. In vitro studies and correlation with in vivo data. Drug Metab Dispos. 1996 Apr;24(4):447-55.
• [5] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [6] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [7] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [8] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [9] Azimilide. Drugs. 2000 Feb;59(2):271-7; discussion 278-9.
• [10] Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
• [11] Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol. 2005 Dec;167(6):1477-84.
• [12] Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells. Metallomics. 2018 Mar 1;10(3):414-425.
• [13] Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997 Jul;16(7):871-81.
• [14] Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52.
• [15] Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
• [16] The organic cation transporters (OCT1, OCT2, EMT) and the plasma membrane monoamine transporter (PMAT) show differential distribution and cyclic expression pattern in human endometrium and early pregnancy decidua. Mol Reprod Dev. 2007 Oct;74(10):1303-11.
• [17] Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet. 2005 Oct;20(5):379-86.
• [18] A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
• [19] Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
• [20] Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol. 2010 Apr;298(4):F997-F1005.
• [21] Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine. Antimicrob Agents Chemother. 2011 Jul;55(7):3091-8.
• [22] Reduced renal clearance of a zwitterionic substrate cephalexin in MATE1-deficient mice. J Pharmacol Exp Ther. 2010 Aug;334(2):651-6.
• [23] Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate. Clin Pharmacol Ther. 2019 May;105(5):1187-1195.
• [24] Expression of Organic Anion Transporter 1 or 3 in Human Kidney Proximal Tubule Cells Reduces Cisplatin Sensitivity. Drug Metab Dispos. 2018 May;46(5):592-599.
• [25] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [26] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [27] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [28] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [29] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [30] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [31] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [32] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [33] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [34] Ethnic-Related Sodium Voltage-Gated Channel Subunit 5 Polymorphisms Shape the In Vitro Pharmacological Action of Amiodarone upon Na(v)1.5. Mol Pharmacol. 2021 Jun;99(6):448-459. doi: 10.1124/molpharm.120.000176. Epub 2021 Apr 6.
• [35] Flecainide test in Brugada syndrome: a reproducible but risky tool. Pacing Clin Electrophysiol. 2003 Jan;26(1P2):338-41. doi: 10.1046/j.1460-9592.2003.00045.x.
• [36] Inhibitory effects of cannabidiol on voltage-dependent sodium currents. J Biol Chem. 2018 Oct 26;293(43):16546-16558. doi: 10.1074/jbc.RA118.004929. Epub 2018 Sep 14.
• [37] Regulatory effects of non-steroidal anti-inflammatory drugs on cardiac ion channels Nav1.5 and Kv11.1. Chem Biol Interact. 2021 Apr 1;338:109425. doi: 10.1016/j.cbi.2021.109425. Epub 2021 Feb 19.
• [38] Quantitative proteomic analysis of HepG2 cells treated with quercetin suggests IQGAP1 involved in quercetin-induced regulation of cell proliferation and migration. OMICS. 2009 Apr;13(2):93-103. doi: 10.1089/omi.2008.0075.
• [39] Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol Appl Pharmacol. 2013 Oct 1;272(1):245-55.
• [40] Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2016 Apr 1;296:42-53. doi: 10.1016/j.taap.2016.01.015. Epub 2016 Jan 25.
• [41] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [42] Modulation of the heart's electrical properties by the anticonvulsant drug retigabine. Toxicol Appl Pharmacol. 2017 Aug 15;329:309-317. doi: 10.1016/j.taap.2017.06.018. Epub 2017 Jun 20.
• [43] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [44] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [45] Inhibition of cardiac potassium currents by pentobarbital. Naunyn Schmiedebergs Arch Pharmacol. 2002 Jan;365(1):29-37. doi: 10.1007/s00210-001-0490-1. Epub 2001 Nov 8.